OWLT Sandbridge Aquisition Corp

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

OWLET, INC.

(Name of Issuer)

Class A Common Stock, $0.0001 par value per share

(Title of Class of Securities)

69120X107

(CUSIP Number)

Lior Susan

Managing Member

Eclipse Ventures

514 High Street, Suite 4

Palo Alto, CA 94301

(650) 720-4667

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 17, 2023

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Explanatory Note:

This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”), of Owlet, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 1. supplements and amends the Schedule 13D relating to the Class A Common Stock of the Issuer that was filed with the Commission on July 26, 2021 (the “Original Schedule 13D”). Only those items that are reported are hereby amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.

Item 2. Identity and Background.

(a) This Statement is being filed by Eclipse Ventures Fund I, L.P. (“Eclipse I”), Eclipse Ventures GP I, LLC (“Eclipse I GP”), Eclipse Continuity Fund I, L.P. (“Eclipse Continuity I”), Eclipse Continuity GP I, LLC (“Eclipse Continuity GP”), Eclipse Early Growth Fund I, L.P. (“Eclipse EGF I”) and Eclipse Early Growth GP I, LLC (“Eclipse EG GP I”, and together with Eclipse I, Eclipse I GP, Eclipse Continuity I and Eclipse EGF I, the “Reporting Entities” or “Eclipse”) and Lior Susan (“Mr. Susan”), a member of the Issuer’s board of directors (the “Board”). The Reporting Entities and the Mr. Susan are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached hereto as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.

(b) The address of the principal offices of each Reporting Entity and the business address of each Reporting Individual is c/o Eclipse Ventures, 514 High Street, Suite 4, Palo Alto, California 94301.

(c) Each Reporting Entity is a venture capital investment entity. Mr. Susan is engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes. Mr. Susan is the sole managing member of (i) Eclipse Continuity GP, the general partner of Eclipse Continuity I, (ii) Eclipse I GP, the general partner of Eclipse I and (iii) Eclipse EG GP I, the general partner of Eclipse EGF I.

(d) During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Each of Eclipse Continuity GP, Eclipse I GP and Eclipse EG GP I is a limited liability company organized under the laws of the State of Delaware. Each of Eclipse Continuity I, Eclipse I and Eclipse EGF I is a limited partnership organized under the laws of the State of Delaware. Mr. Susan is a citizen of the United States of America.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Schedule 13D is hereby amended by adding the following as the last paragraph thereof:

On February 17, 2023 (the “Closing Date”), pursuant to the Investment Agreement (as defined in Item 6) Eclipse EGF I purchased (i) 20,200 shares of Series A Convertible Preferred Stock that, subject to the Individual Holder Share Cap, are initially convertible into 41,224,489 shares of the Issuer’s Class A Common Stock and (ii) a Warrant to purchase, subject to the Individual Holder Share Cap, 74,204,080 shares of Class A Common Stock for a purchase price of $1,000.00 per share of Series A Convertible Preferred Stock and an aggregate purchase price of $20,200,000.00.

Item 4. Purpose of Transaction.

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Class A Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Class A Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

Mr. Susan is a member of the Board. In addition, Mr. Susan, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer’s nonemployee director compensation program.

Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a) and (b) See Items 7-11 of the cover pages of this Statement and Item 2 above.

(c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

(d) Under certain circumstances set forth in the limited partnership agreements of Eclipse Continuity I, Eclipse I and Eclipse EGF I, the general partner and limited partners of each of Eclipse Continuity I, Eclipse I and Eclipse EGF I may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Item 6 of the Schedule 13D is amended and supplemented as follows:

On the Closing Date, the Issuer entered into an Investment Agreement (the “Investment Agreement”) with Eclipse EGF I, pursuant to which Eclipse EGF I purchased (i) 20,200 shares of Series A Convertible Preferred Stock that, subject to the Individual Holder Share Cap, are initially convertible into 41,224,489 shares of the Issuer’s Class A Common Stock, and (ii) a warrant (the “Warrant”) to purchase, subject to the Individual Holder Share Cap, 74,204,080 shares of Class A Common Stock for a purchase price of $1,000.00 per share of Series A Convertible Preferred Stock and an aggregate purchase price of $20,200,000.00. The Investment Agreement is filed herewith as Exhibit 2, and any description thereof is qualified in its entirety by reference thereto.

The Warrant has a five-year term and an exercise price that is equal to $0.333 per share. The Warrant also provides for an exercise on a cash or cashless net exercise basis at any time after the Closing Date and will be automatically exercised on a cashless basis if not exercised prior to the expiration of the five-year term. Upon a fundamental change or other liquidation event, the Warrant will automatically net exercise if not exercised before the consummation of such event. The Form of Warrant is filed herewith as Exhibit 3, and any description thereof is qualified in its entirety by reference thereto.

In connection with the purchase of Series A Convertible Preferred Stock, Eclipse Continuity I, Eclipse I and Eclipse EGF I entered into an Amended and Restated Stockholders Agreement with the Issuer, dated February 17, 2023 (the “Amended Stockholders Agreement”). The Amended Stockholders Agreement provides that (a) until such time as Eclipse beneficially owns less than 20.0% of the total voting power entitled to elect directors, Eclipse shall be entitled to nominate two individuals to the Board (the “Eclipse Directors” and each, an “Eclipse Director”) and (b) from such time that Eclipse beneficially owns less than 20.0% of the total voting power entitled to elect directors and until Eclipse beneficially owns less than 10.0% of the total voting power entitled to elect directors, Eclipse will be entitled to nominate one Eclipse Director. The Amended Stockholders Agreement also provides that Mr. Susan shall serves as the Chairperson of the Board and that Jayson Knafel shall be appointed to the Board as a Class II Director for a term expiring at the Issuer’s annual meeting of stockholders to be held in 2023 (the “2023 Annual Meeting”). The Amended Stockholders Agreement is filed herewith as Exhibit 4, and any description thereof is qualified in its entirety by reference thereto.

On the Closing Date, the Issuer filed a Certificate of Designation (the “Certificate of Designation”) setting forth the terms, rights, obligations and preferences of the Series A Convertible Preferred Stock.

Ranking and Dividends

The Series A Convertible Preferred Stock ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the Class A Common Stock and all other classes or series of equity securities of the Company established after the Closing Date, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A Convertible Preferred Stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the Closing Date, the terms of which expressly provide that it ranks on parity with the Series A Convertible Preferred Stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after the Closing Date, the terms of which expressly provide that it ranks senior to the Series A Convertible Preferred Stock with respect to dividend rights, rights of redemption and rights upon a liquidation event.

The Series A Convertible Preferred Stock has a liquidation preference of $1,000.00 per share (the “Liquidation Preference”). The Issuer has agreed not to declare, pay or set aside any dividends on shares of Class A Common Stock unless the holders of the Series A Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series A Convertible Preferred Stock in an amount at least equal to the product of (i) the dividend payable on each share of Class A Common Stock multiplied by (ii) the number of shares of Class A Common Stock issuable upon conversion of a share of Series A Convertible Preferred Stock to Class A Common Stock thereunder, in each case calculated on the record date for determination of holders entitled to receive such dividend.

Voting and Consent Rights

Holders of Series A Convertible Preferred Stock are entitled to vote with the holders of shares of Class A Common Stock on an as-converted to common basis at any annual or special meeting of stockholders of the Issuer, and not as a separate class, except as required by Delaware law.

Additionally, for so long as any Series A Convertible Preferred Stock remain outstanding, the Issuer will be prohibited, without the consent of the holders of at least a majority of the Series A Convertible Preferred Stock, from taking various corporate actions, including:

Registration Rights

As promptly as reasonably practicable after the Closing Date, but in any event within twenty (20) business days after the later of (i) the Closing Date or (ii) the filing of the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2022, the Issuer will file and use commercially reasonable efforts to cause to be declared effective or otherwise become effective pursuant to the Securities Act of 1933, as amended (the “Securities Act”) a shelf registration statement to register the resale of all the shares of Class A Common Stock issuable upon conversion or exercise of the Series A Convertible Preferred Stock or Warrant (the “Resale Shelf”). Shares of Class A Common Stock underlying the Series A Convertible Preferred Stock and Warrant held by Eclipse EGF I will be considered “Registrable Securities” for purposes of that certain Amended and Restated Registration Rights Agreement, dated as of July 15, 2021, by and among the Issuer and the holders party thereto (the “Rights Agreement”), which will entitle such holders to the demand and piggyback registration rights set forth therein. The Rights Agreement is filed herewith as Exhibit 5, and any description thereof is qualified in its entirety by reference thereto.

The Certificate of Designation is filed herewith as Exhibit 6, and any description thereof is qualified in its entirety by reference thereto.

The Certificate of Designation and the Warrant include certain provisions that prevent Eclipse EGF I, until Stockholder Approval (as defined below) is obtained, from converting its Series A Convertible Preferred Stock, voting its Series A Convertible Preferred Stock on an as-converted-to-Class A Common Stock basis or exercising the Warrant, as applicable, to the extent such action would result in Eclipse EGF I, or any group (within the meaning of Section 13(d)(3) of the Exchange Act) that includes Eclipse EGF I, beneficially owning in excess of 29.99% of the Issuer’s outstanding Class A Common Stock (the “Individual Holder Share Cap”).

The Issuer has agreed in the Investment Agreement to include a proposal in the definitive proxy statement for its 2023 Annual Meeting, soliciting approval by the Issuer’s stockholders to issue Class A Common Stock to Eclipse such that the Individual Holder Share Cap shall no longer apply in accordance with applicable law and the rules and regulations of the NYSE (the “Stockholder Approval”). If the Stockholder Approval is not obtained at the 2023 Annual Meeting, the Issuer has agreed to use its commercially reasonable efforts to call a special stockholder meeting within four months of the 2023 Annual Meeting to obtain the Stockholder Approval as contemplated and if the Stockholder Approval is not obtained at such special meeting, the Issuer shall again include the Stockholder Approval for its annual stockholder meeting for 2024.

Item 7. Material to be Filed as Exhibits.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 27, 2023